Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Vainstein

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal of Hematology & Oncology|April 9, 2014
Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiationZoya Gluzman-Poltorak, Sarita R Mendonca, Vladimir Vainstein, et al.
International Journal of Molecular Sciences|September 23, 2022
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic LeukemiaShlomzion Aumann, Adir Shaulov, Arnon Haran, et al.
Leukemia & Lymphoma|December 29, 2021
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcomeEyal Lebel, Vladimir Vainstein, Maayan Ashkenazi, et al.
Clinical Nuclear Medicine|May 21, 2020
Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk AssessmentBoaz Nachmias, Jeremy Godefroy, Eyal Rozenbach, et al.
American Journal of Hematology|January 3, 2014
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromesSarah A Buckley, Megan Othus, Vladimir Vainstein, et al.
Acta Haematologica|January 30, 2025
Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic LeukemiaUriel Oanunu, Noa Gross Even-Zohar, Shlomzion Aumann, et al.
Cancers|November 25, 2023
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of InterestBoaz Nachmias, Svetlana Krichevsky, Moshe E Gatt, et al.
Plos One|September 15, 2011
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationEva Jager, Vincent H J van der Velden, Jeroen G te Marvelde, et al.
Experimental Hematology & Oncology|April 15, 2014
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effectsMamata S Gokhale, Vladimir Vainstein, Jamie Tom, et al.
European Journal of Haematology|December 31, 2024
Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second RemissionAvraham Frisch, Chezi Ganzel, Yishai Ofran, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of Hematology & Oncology|April 9, 2014
Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiationZoya Gluzman-Poltorak, Sarita R Mendonca, Vladimir Vainstein, et al.
International Journal of Molecular Sciences|September 23, 2022
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic LeukemiaShlomzion Aumann, Adir Shaulov, Arnon Haran, et al.
Leukemia & Lymphoma|December 29, 2021
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcomeEyal Lebel, Vladimir Vainstein, Maayan Ashkenazi, et al.
Clinical Nuclear Medicine|May 21, 2020
Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk AssessmentBoaz Nachmias, Jeremy Godefroy, Eyal Rozenbach, et al.
American Journal of Hematology|January 3, 2014
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromesSarah A Buckley, Megan Othus, Vladimir Vainstein, et al.
Acta Haematologica|January 30, 2025
Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic LeukemiaUriel Oanunu, Noa Gross Even-Zohar, Shlomzion Aumann, et al.
Cancers|November 25, 2023
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of InterestBoaz Nachmias, Svetlana Krichevsky, Moshe E Gatt, et al.
Plos One|September 15, 2011
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationEva Jager, Vincent H J van der Velden, Jeroen G te Marvelde, et al.
Experimental Hematology & Oncology|April 15, 2014
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effectsMamata S Gokhale, Vladimir Vainstein, Jamie Tom, et al.
European Journal of Haematology|December 31, 2024
Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second RemissionAvraham Frisch, Chezi Ganzel, Yishai Ofran, et al.
Pageof 5